S. aureus Engineered Phage Development & Genome Editing

Q: Why is editing phages harder than editing phages like λ or T7?

S. aureus has a thick peptidoglycan wall (20–80 nm) that impedes infection and DNA delivery, and many clinical isolates carry restriction-modification systems that destroy incoming plasmid or phage DNA. We use restriction-modification-deficient recipients such as RN4220 and optimized DNA delivery methods to overcome these barriers.

Q: Can you deliver a scarless, marker-free edited phage?

Yes. Our homologous recombination and CRISPR-assisted workflows introduce edits without selectable resistance markers, so the final phage carries only the intended change. This supports downstream biosafety assessment and regulatory submission, and preserves a non-recombinant status where applicable.

Q: How do you validate that an edited phage is correct and pure?

Every project runs from single-plaque purification through PCR identification and Sanger or whole-genome sequencing. We also assess wild-type background and, where relevant, host-range and lytic spectrum, then deliver a report with sgRNA, primer, and donor sequences.

Q: Do you work with customer-provided phages or hosts?

Yes. We edit customer-supplied phages and propagate them on your designated S. aureus host, provided the strains are documented and permitted under local containment rules. Share genome sequences and any prior editing attempts during consultation to accelerate design.

Q: How do edited phages move to larger-scale or therapeutic production?

Validated edited phages transfer to our phage fermentation and large-scale production service, which operates documentation-ready workflows suitable for downstream GMP transition.

Inquiry

OverviewServicesSample RequirementsAdvantagesApplicationsCase StudyFAQs

Overview

Service Overview

Staphylococcus aureus is among the most consequential opportunistic pathogens in clinical medicine, responsible for severe bloodstream, skin, and device-associated infections that grow harder to treat as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate strains spread. Engineered phages offer a precision alternative that acts specifically on target staphylococcal strains, minimizing collateral damage to the commensal microbiota.

Creative BioMart Microbe provides S. aureus Engineered Phage Development & Genome Editing that turns native phages into programmable “nanoweapons” against drug-resistant S. aureus. By applying targeted genome editing, we enhance lytic efficiency, broaden host range, and remove lysogenic or virulence-related sequences and reduce immunogenicity by modifying surface-exposed proteins — tailoring each phage to a therapeutic, diagnostic, or research goal.

Our S. aureus program is one module of a broader phage genome editing portfolio spanning λ, Klebsiella pneumoniae, T7, and M13 systems. Edited phages hand off seamlessly to our phage fermentation and large-scale production service for downstream scale-up under documentation-ready workflows.

Conceptual illustration of S. aureus engineered phage development showing a drug-resistant S. aureus bacterium with thick peptidoglycan cell wall and biofilm matrix being targeted by a CRISPR-engineered phage carrying enhanced lytic proteins, demonstrating host-range expansion and biofilm penetration capabilities.
Figure 1. Conceptual overview of S. aureus engineered phage development — CRISPR-engineered phages are tailored to overcome the thick peptidoglycan cell wall, expand host range across MRSA lineages, and penetrate established biofilms for enhanced therapeutic efficacy.

Host Biology & Clinical Relevance

S. aureus Characteristic	Relevance to Phage Engineering & Genome Editing
Thick peptidoglycan cell wall (20–80 nm)	A physical barrier to infection and to plasmid or phage-DNA delivery, demanding optimized electroporation and restriction-modification-deficient recipients such as RN4220.
MRSA and USA300 hypervirulent lineages	Editing must cover diverse clinical isolates; tail-fiber and receptor-binding engineering expands receptor recognition across serotypes.
Robust biofilm architecture	Phages engineered to express depolymerases penetrate the matrix, and endolysin integration strengthens killing within established biofilms.

Services

Service Workflow

Each project runs through a standardized four-stage pipeline built around CRISPR/Cas9 counter-selection, with the donor design and host selection customized to your phage and target.

Horizontal six-step service workflow banner for S. aureus phage engineering and genome editing: project consultation and design, donor and sgRNA construct development, host transformation with Cas9 counter-selection, plaque purification and layered validation, sequence confirmation and project reporting, and optional scale-up to fermentation production.

Inquiry

Editing Strategies

We select the mechanism that best fits your phage genome size, target locus, and desired edit.

Genome Editing Strategies

Strategy	Mechanism	Best For
CRISPR/Cas9 counter-selection (primary)	Cas9/sgRNA cleaves wild-type phage genomes during infection; homology-directed repair enriches mutants	Point mutations, knockouts, and insertions in lytic phages (via CRISPR/Cas9 counter-selection during infection) and temperate phages (via prophage engineering in the lysogenic host)
Homologous recombination	Donor template (plasmid or oligonucleotide) with homology arms drives precise base substitution or sequence insertion	Targeted integration, gene replacement, and scarless edits
Host strain engineering & DNA delivery optimization	Restriction-modification-deficient intermediate hosts and optimized DNA delivery to overcome Gram-positive transformation barriers	Overcoming low transformation efficiency and phage or DNA restriction barriers in staphylococci

Service Details

3D illustration of a Staphylococcus aureus phage with a gene segment removed and a colony plate representing a knockout mutant.

Gene Knockout / Inactivation

Precise deletion of non-essential phage genes to dissect function or reduce genome load. We design flanking homology arms and use CRISPR/Cas9 counter-selection to recover scarless mutants, then verify by PCR and sequencing. Deliverables are plaque-purified knockout lysates with a full editing report.

3D illustration of a Staphylococcus aureus phage carrying an inserted glowing reporter gene representing cargo integration.

Gene Integration / Overexpression

Insertion of reporter genes or functional enzyme tags at non-coding or defined loci to arm phages with new functions. Using homologous recombination or CRISPR-assisted integration, we place cargo such as fluorescent proteins or depolymerases without disrupting essential genes. Each clone is sequence-verified and titered.

3D illustration of a Staphylococcus aureus phage DNA helix with a single base highlighted for a point mutation edit.

Point Mutation / Modification

Base-level edits that mimic natural variants or remodel protein functional sites to dissect resistance-suppression mechanisms. Silent and missense changes are introduced via homology-directed repair and enriched by Cas9 counter-selection. We confirm the exact genotype by Sanger sequencing before delivery.

3D illustration of a customizable Staphylococcus aureus phage platform with interchangeable tool modules representing tailored editing.

Customized Solutions

Tailored editing strategies for temperate or virulent S. aureus phages from diverse sources, including customer isolates. We adapt the workflow — counter-selection, recombination, or assembly — to your phage’s genome size and biology. Consultation defines target, host, and deliverables up front.

Deliverables & QC

High-titer, plaque-purified phage lysate.
Sanger sequencing confirmation of the edited locus, with whole-genome sequencing available upon request.
Wild-type background assessment by plaque morphology and host-range screening; off-target evaluation by targeted sequencing.
Host-range and lytic activity profiling where relevant.
Project report with sgRNA, primer, and donor-plasmid sequences.

Sample Requirements

To initiate a project, provide as much of the following as possible. Our team will advise on any gaps during the consultation.

Required Information	Optional Information	Not Accepted
Target phage (isolated lysate) and/or host S. aureus strain Desired edit: knockout, point mutation, insertion, or host-range change, with target coordinates where known Intended application and downstream use (research, therapeutic, diagnostic)	Existing phage or host genome sequence or annotation Preferred editing strategy or prior attempt data sgRNA target sites or donor-plasmid homology-arm designs	Pathogenic strains restricted by local containment law without prior approval Phages with no documented host or sequence context

Recommended Input by Project Type

Project Type	Preferred Input	Typical Timeline
Gene knockout / inactivation	Phage lysate + host strain + target gene	3–5 weeks
Gene integration / overexpression	Phage + donor design (cargo + homology arms)	4–6 weeks
Point mutation / modification	Phage lysate + host + target locus	3–5 weeks
Customized (temperate / virulent)	Phage from any source + host strain	5–8 weeks

Lysates should be shipped on dry ice with glycerol backups; genomic DNA is accepted in ethanol or TE at 4°C. Because many clinical S. aureus isolates carry restriction-modification systems, provide host strain context so we can select an appropriate recipient such as RN4220. Contact our team for shipping instructions and compliance requirements before sending biological materials.

Inquiry

Our Advantages

End-to-end validation — Verification spans single-plaque screening through whole-genome sequencing, so every delivered phage is confirmed at the sequence level.
Scarless editing — No unnecessary resistance markers are introduced, keeping edited phages compatible with downstream biosafety assessment and regulatory submission.
Host-matched S. aureus engineering — We deploy restriction-modification-deficient recipients and optimized DNA delivery methods to overcome the Gram-positive cell-wall and transformation barriers unique to S. aureus.
Integrated scale-up pathway — Edited phages transfer directly to our phage fermentation and large-scale production service under documentation-ready workflows.

Applications

3D icon of a Staphylococcus aureus phage with a deleted gene segment representing functional genomics.

Functional Genomics

Precise deletion or modification of early and late genes to study the lytic cycle, progeny packaging, and host interactions under controlled conditions.

3D icon of a Staphylococcus aureus phage tail fiber changing shape to recognize multiple host strains representing host-range engineering.

Host-Range Engineering

Tail-fiber protein point mutation or domain swapping enables cross-serotype recognition, extending coverage to MRSA and USA300 hypervirulent lineages.

3D icon of a Staphylococcus aureus phage with an integrated glowing reporter gene representing synthetic biology.

Synthetic Biology

Reporter gene integration, such as fluorescent proteins, supports real-time infection monitoring and high-throughput screening of phage–host dynamics.

3D icon of a Staphylococcus aureus phage expressing a depolymerase to break a biofilm matrix representing engineered phage development.

Engineered Phage Development

Endolysin or depolymerase gene integration enhances biofilm penetration and killing, turning native phages into potent anti-biofilm agents.

Case Study

Case Study 1: Engineered Endolysin Effectors for Anti-Biofilm S. aureus Control

A panel of 12 engineered endolysin-based proteins was constructed by modular recombination of catalytic and cell-wall-binding domains from native staphylococcal endolysins. LysRODIΔAmi and ClyRODI-H5 exhibited the highest specific lytic activity, 5 to 50 times higher than the remaining variants. LysRODIΔAmi reduced planktonic S. aureus Sa9 by ~6 log units below the detection limit within 5 min and removed 76% of 8-h preformed biofilm, while ClyRODI-H5 achieved 65% removal. The lead protein remained stable at temperatures up to 50°C and across pH 3–9, with a shelf life of up to 6 months and no cytotoxicity toward human keratinocytes even at 22.1 μM. These effector proteins illustrate the type of cargo that can be integrated into engineered S. aureus phages for enhanced anti-biofilm activity in therapeutic development.

Bar chart of antibiofilm activity of engineered proteins against Staphylococcus aureus 15981 biofilms, showing biofilm inhibition and removal percentages.
Figure 2. Antibiofilm activity of engineered proteins against S. aureus 15981 biofilms. Bars represent means ± SDs (n = 6); distinct letters indicate significant differences (p < 0.05, ANOVA with SLK post hoc test). (Gutiérrez et al., 2021)

FAQs

Q: Why is editing S. aureus phages harder than editing E. coli phages like λ or T7?

A: S. aureus has a thick peptidoglycan wall (20–80 nm) that impedes infection and DNA delivery, and many clinical isolates carry restriction-modification systems that destroy incoming plasmid or phage DNA. We use restriction-modification-deficient recipients such as RN4220 and optimized DNA delivery methods to overcome these barriers.

Q: Can you deliver a scarless, marker-free edited phage?

A: Yes. Our homologous recombination and CRISPR-assisted workflows introduce edits without selectable resistance markers, so the final phage carries only the intended change. This supports downstream biosafety assessment and regulatory submission, and preserves a non-recombinant status where applicable.

Q: How do you validate that an edited S. aureus phage is correct and pure?

A: Every project runs from single-plaque purification through PCR identification and Sanger or whole-genome sequencing. We also assess wild-type background and, where relevant, host-range and lytic spectrum, then deliver a report with sgRNA, primer, and donor sequences.

Q: Do you work with customer-provided S. aureus phages or hosts?

A: Yes. We edit customer-supplied phages and propagate them on your designated S. aureus host, provided the strains are documented and permitted under local containment rules. Share genome sequences and any prior editing attempts during consultation to accelerate design.

Q: How do edited phages move to larger-scale or therapeutic production?

A: Validated edited phages transfer to our phage fermentation and large-scale production service, which operates documentation-ready workflows suitable for downstream GMP transition.

References:

Gutiérrez, D., et al. (2021). Design and selection of engineered lytic proteins with Staphylococcus aureus decolonizing activity. Frontiers in Microbiology, 12, 723834.

Services

Inquiry